Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
about
Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalTrabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
P2860
Q31061574-325AECAE-173C-456D-8B31-8B930395A715Q34573847-F45DEA53-E483-4FDB-8998-7FDBB8AF4C06Q38097338-D10BD9F6-245B-4BFD-903E-72E82D183456Q38098483-4A7396F5-9123-46B2-B08E-A946A912B291Q38098484-DA5DB8DD-CCE5-4363-AAD3-F89BCCEA8BB1Q38133381-18DA7703-1615-4637-87BB-E5D776CFE974Q38149091-52385EC8-1828-4791-89B4-46340E3BB236Q38151578-00B9ABCC-5835-4FC8-9ACF-D21D3E8655BAQ39841853-C7073116-7CE1-4F22-9648-1FBDEFF18644Q41636230-6C842679-1C58-4C91-BECA-0BC9EA1FF6A0Q50709249-DB55EB03-AD09-47B8-B20E-2DBBF669B9F5
P2860
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rituximab for the first-line m ...... E single technology appraisal.
@en
type
label
Rituximab for the first-line m ...... E single technology appraisal.
@en
prefLabel
Rituximab for the first-line m ...... E single technology appraisal.
@en
P2093
P2860
P921
P1433
P1476
Rituximab for the first-line m ...... E single technology appraisal.
@en
P2093
Adrian Bagust
Angela Boland
Chris Proudlove
James Oyee
Janette Greenhalgh
Juliet Hockenhull
Michaela Blundell
Patrick Chu
Sophie Beale
Yenal Dundar
P2860
P2888
P304
P356
10.1007/S40273-013-0043-8
P577
2013-05-01T00:00:00Z